Source comparison
Sermorelin Dosage Body Composition 2026: Clinical Comparison
100 mcg +18–25% +0.4 to +0.8 −1.2 to −1.8 5–8% Minimal body composition effect; suitable for initial tolerance assessment only 200 mcg +35–48% +1.0 to +1.5 −2.1 to −2.9 8–12% Threshold dose for measurable lean mass preservation during caloric restriction 300 m
This comparison does not assign a generated winner or score.
- 100 mcg
- +18–25%
- +0.4 to +0.8
- −1.2 to −1.8
- 5–8%
- Minimal body composition effect; suitable for initial tolerance assessment only
- 200 mcg
- +35–48%
- +1.0 to +1.5
- −2.1 to −2.9
- 8–12%
- Threshold dose for measurable lean mass preservation during caloric restriction
- 300 mcg
- +52–68%
- +1.6 to +2.2
- −3.4 to −4.6
- 10–15%
- Optimal dose-response ratio; maximises body composition benefit with acceptable tolerance
- 400 mcg
- +60–74%
- +1.8 to +2.4
- −3.8 to −5.1
- 15–22%
- Marginal benefit over 300 mcg; higher adverse event rate without proportional efficacy gain
- 500 mcg
- +65–78%
- +1.9 to +2.5
- −4.0 to −5.3
- 20–28%
- Diminishing returns; receptor saturation and desensitisation risk outweigh incremental benefit
- 600+ mcg
- +68–82%
- +2.0 to +2.6
- −4.1 to −5.4
- 28–35%
- Not recommended; significant adverse event increase with negligible additional body composition effect